Levilimab for COVID-19: real-time analysis

Download Image

Post

c19early.org

Levilimab for COVID-19

1 study with 206 patients

Serious outcome risk

Levilimab

Control

COVID-19 Levilimab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)0%

Mortality (1)0%

RCTs (1)0%

Late (1)0%

00.511.5+

← Levilimab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Sep 29 2021	Lomakin et al., Inflammation Research, doi:10.1007/s00011-021-01507-5	The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study
Sep 29 2021	70% lower ICU admission (p=0.08) and 65% greater improvement (p<0.0001). RCT 206 severe COVID-19 patients not requiring mechanical ventilation, showing higher sustained clinical improvement and lower ICU admission with levilimab. There was no difference in mortality.